Genetic Signatures Delivers Strong Growth and Secures First U.S. Contract in 1H FY25

Genetic Signatures (ASX: GSS) achieved significant milestones in the first half of FY25, reporting 136% revenue growth to AU$8.5 million, driven by strong respiratory sales in Australia. Gross margins improved to 59%, and underlying losses reduced by 20% to AU$8.4 million. However, a AU$6.8 million impairment charge contributed to a statutory loss of AU$15.2 million.

A new strategic direction has been set, shifting from internal instrument development to customizing commercially available automated solutions, reducing costs and accelerating time-to-market. The company secured its first U.S. commercial contract in February 2025, marking a key step in its U.S. expansion.

With AU$40.8 million in cash reserves, Genetic Signatures is well-positioned for continued growth, focusing on expanding its EasyScreen™ Gastrointestinal Parasite Detection Kit and building a strong pipeline in global markets.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com